StockData
Celularity Inc logo

Celularity Inc (CELU) company profile

CELUNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Oct 20, 2026Score 7/30
$0.57−0.05 (-7.75%)

Close on Nov 17, 2026Market cap $18.53MP/E –Yield –

About Celularity

Pharmaceutical Preparations, SIC 2834

Celularity is a biotechnology company developing cell therapy products and biobanking services. The company specializes in cellular medicine, utilizing proprietary technology rights and cellular biological materials to develop therapeutic treatments. Alongside cell therapy research and development, it conducts biobanking operations and related service activities. The business also enters into intellectual property agreements, licensing arrangements, and research-oriented contracts. Its customer base includes commercial clients, institutional research partners, and healthcare organizations utilizing its biobanking services and cellular products.

The company operates office, laboratory, and manufacturing facilities located in Florham Park, New Jersey, where it conducts its core operational and scientific activities. Celularity maintains equipment and leasehold improvements at this facility to support its production and biobanking capacity. All primary operations, production capabilities, and corporate administration are concentrated at this single site in the United States, with corporate activities conducted from its New Jersey headquarters.

Summary of the business section of Celularity's latest annual report, written by StockData.

Company profile

Company

Legal name
Celularity Inc
Headquarters
Florham Park, NJ
Address
170 Park Ave 07932
Phone
(908) 768-2170
Employees
115, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
EisnerAmper LLP, Iselin, New Jersey

Stock & identifiers

Ticker
CELU
Exchange
Nasdaq
IPO date
May 21, 2019
Shares outstanding
32M, Oct 19, 2026
Public float
$28.40M, Jun 30, 2025
Filer category
<br>Emerging growth company
Stock splits
1-for-10 reverse, Jul 30, 2024; 1-for-10 reverse, Feb 29, 2024; 3-for-1, Aug 19, 2021
SEC CIK
1752828
CUSIP
151190204
ISIN
US1511902041
FIGI
BBG00P2RTT34
Share class FIGI
BBG00P2RTT43
EIN
83-1702591

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Robert J. HaririChief Executive Officer, Director2,853,553
Stephen BrigidoPres., Functional Regeneration9,742
John R. HainesSenior Exec Vice President30,179
Joseph DosSantosInterim CFO–
David C. BeersChief Financial Officer18,201
Philip Alan BarachDirector–
Geoffrey M.D. LingDirector256,026
Diane L. ParksDirector520,021
Peter DiamandisDirector394,150
Vincent LeVienDirector153,847
Dean C. KehlerDirector797,858
Richard J. BermanDirector67,416

Executive compensation, fiscal 2024

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsOtherTotalvs. prior year
Robert J. Hariri, M.D., Ph.D.
Chief Executive Officer
$179.14K$634.56K$35.26K$848.96K-31%
John Haines
Senior Executive Vice President, Chief Administrative Officer and Corporate Secretary
$434.38K$46.66K$35.97K$517.01K-37%
David Beers
Chief Financial Officer(4)
$369.22K$39.66K$36.16K$445.04K-30%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

SPAC offering

Type
SPAC (blank check) IPO of units
Final prospectus filed
May 21, 2019
Offer price
$10.00
Securities offered
25,000,000
Gross proceeds
$250.00M
Exchange
Nasdaq
First trading day
Jul 15, 2019
First-day close
$10.34+3.4%
Lock-up ends (est.)
Jan 11, 2020

“Each unit has an offering price of $10.00 and consists of one share of our Class A common stock and one -half of one redeemable warrant.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“had 115 full-time employees and 1 non-employee leased worker, most of whom are located at our Florham Park facility.”

Corporate history

Events identified from SEC filings

DateEventDetails
Aug 14, 2026Late filingNotification of late filing
Jul 29, 2026Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Jul 22, 2026DelistingNotice of delisting from exchange (Form 25)
Jun 12, 2026Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
May 15, 2026Late filingNotification of late filing
Mar 31, 2026Late filingNotification of late filing
Apr 23, 2025Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Mar 31, 2025Late filingNotification of late filing
Nov 29, 2024Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Nov 15, 2024Late filingNotification of late filing
Oct 21, 2024Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Aug 23, 2024Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Aug 16, 2024Late filingNotification of late filing
Aug 5, 2024Auditor changeChange in certifying accountant (8-K Item 4.01)
May 24, 2024Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
May 15, 2024Late filingNotification of late filing
Apr 22, 2024Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Apr 1, 2024Late filingNotification of late filing
Nov 24, 2023Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Nov 14, 2023Late filingNotification of late filing
May 15, 2023Late filingNotification of late filing
Mar 17, 2023Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Aug 16, 2021Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Aug 16, 2021Late filingNotification of late filing
Jul 22, 2021Auditor changeChange in certifying accountant (8-K Item 4.01)
Jul 22, 2021Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Jul 19, 2021Name changeName changed from GX Acquisition Corp. to Celularity Inc
Jul 19, 2021DelistingNotice of delisting from exchange (Form 25)
May 18, 2021Late filingNotification of late filing
Jan 25, 2021MergerRegistration of securities for a merger or exchange offer (S-4)

See a number that looks wrong?